Regulation of RUNX3 Expression by DNA Methylation in Prostate Cancer
Authors Yang X, Wang S, Reheman A
Received 10 February 2020
Accepted for publication 7 July 2020
Published 27 July 2020 Volume 2020:12 Pages 6411—6420
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Eileen O'Reilly
Xin Yang,1,* Shumei Wang,2,* Alimu Reheman1
1Department of Urology, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People’s Republic of China; 2Urumqi Blood Center, Urumqi, Xinjiang Uygur Autonomous Region, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Alimu Reheman Email firstname.lastname@example.org
Purpose: To investigate the role of DNA methylation in the regulation of Runt-related transcription factor 3 (RUNX3) and the effect of such mechanism on the proliferation of prostate cancer (PCa) cells.
Materials and Methods: The methylation of the RUNX3 in the promoter region in PCa cells was detected by bisulfite-sequencing PCR (BSP). Following treatment of the PCa cells with DNA methylation transferase inhibitor 5-AZA-2ʹ-deoxycytidine (AZA), the effect on methylation level and expression of RUNX3 were analyzed by qRT-PCR, Western blot, and BSP assays. Furthermore, we investigated the effect of the demethylated RUNX3 on proliferation, cell cycle and apoptosis of PCa cells using CCK-8 and flow cytometry assays. Using the DNA methylation transferase (DNMT3b) knockout or overexpression models, the relationship between DNMT3b and RUNX3 methylation was further assessed by qRT-PCR, Western blot and methylation-specific PCR (MSP).
Results: The results indicated that the methylation level of RUNX3 in PCa cell lines was significantly higher than that of normal prostate epithelial (RWPE-1) cells. Furthermore, treatment with AZA not only promoted the demethylation of RUNX3 but also restored the mRNA and protein expression of RUNX3, and the reactivation of expression of the later exhibited its anti-tumor effects through regulation of the cycle progression in PCa cells. Moreover, DNMT3b could regulate the expression level of RUNX3 by altering the DNA methylation of the RUNX3 in PCa cells.
Conclusion: RUNX3 is hypermethylated in a panel of PCa cell lines; inhibition of DNA methylation of RUNX3 could restore its gene expression, which could promote its anticancer effect. Thus, RUNX3 may serve as a novel putative molecular target gene for PCa therapy.
Keywords: prostate cancer, RUNX3, DNA methylation, AZA, DNMT3b
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]